IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
Article first published online: 11 AUG 2009
© 2009 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 7, Issue 10, pages 1703–1710, October 2009
How to Cite
FERRARI, S., MUDDE, G. C., RIEGER, M., VEYRADIER, A., KREMER HOVINGA, J. A. and SCHEIFLINGER, F. (2009), IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 7: 1703–1710. doi: 10.1111/j.1538-7836.2009.03568.x
- Issue published online: 22 SEP 2009
- Article first published online: 11 AUG 2009
- Received 2 April 2008, accepted 23 July 2009
- 1Thrombotic microangiopathies. N Engl J Med 2002; 347: 589–600..
- 2Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223–34., , .
- 3Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235–44..
- 4von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. N Engl J Med 1998; 339: 1578–84., , , , , , , , , , , .
- 5Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–94., .
- 6Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241–3., , , , , , , .
- 7ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262–7., , , , , , , , , , , , , , .
- 8Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815–22., , , , , , , , , , , , , , , , , , , , et al.
- 9Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Ann Biol Clin (Paris) 1994; 52: 57–65., , , .
- 10Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly 2003; 133: 325–32., , , , .
- 11Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765–72., , , , .
- 12Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95: 212–20., , , , , , , , , , .
- 13Immunoglobulin class switching. Curr Opin Immunol 1996; 8: 199–205..
- 14Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 41–8., , , , , , , , , .
- 15IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644–52., , , , , , , , .
- 16The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007; 299: 1–8., , .
- 17IgG subclasses of human autoantibodies. Ann Med Interne (Paris) 1997; 148: 29–38., , , , , .
- 18Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 1986; 137: 3566–71., , .
- 19Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83: 815–7., , , .
- 20Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861–8., , , , , .
- 21Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97: 693–8., , , , , .
- 22Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317: 1554–7., , , , , , , , , , , , , .
- 23Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34–47., .
- 24IgG4 breaking the rules. Immunology 2002; 105: 9–19., .
- 25The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989–2007. Kidney Int Suppl 2009; 75: S52–4..
- 26Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Semin Thromb Hemost 2005; 31: 700–8., .
- 27Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008; 93: 172–7., , .